Critical Insights on Recent Advances in Spinal Muscular Atrophy

CMEO Live and OnDemand

Premiere Date: Tuesday, January 7, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. ABP (MOC)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, January 7, 2021

Begin Activity Now

Faculty


Emma Ciafaloni, MD, FAAN Emma Ciafaloni, MD, FAAN 
Robert C. and Rosalyne H. Griggs Professor in Experimental Therapeutics of Neurologic Disease
Professor of Neurology, Pediatrics and Obstetrics and Gynecology
Director, Pediatric Neuromuscular Medicine
University of Rochester, School of Medicine and Dentistry
Rochester, NY

John Brandsema, MD John Brandsema, MD 
Neurologist and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Assistant Professor of Clinical Neurology
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, PA

Nancy L. Kuntz, MD, FAAN Nancy L. Kuntz, MD, FAAN 
Child Neurologist, Medical Director
Mazza Foundation Neuromuscular Disorders Program & Muscular Dystrophy Association Care Center
Ann & Robert H. Lurie Children's Hospital of Chicago
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL

Statement of Need

Spinal muscular atrophy (SMA) is a leading, fatal, autosomal recessive disorder that affects approximately one in 10,000 live births. Nusinersen was approved as the first targeted therapy for SMA, and since its groundbreaking approval data has been published that demonstrates its efficacy for both infantile- and later-onset SMA populations. Additionally, recent guidelines were published that provide evidence-based recommendations for the diagnosis and management of SMA.

However, despite these advances there are knowledge gaps among health care providers (HCPs) regarding current data on safety and efficacy of approved and emerging therapies, which can result in treatment delays. Closing these gaps will promote early and accurate diagnosis and optimal treatment of patients with SMA.

In this CME Outfitters live and on demand webcast, expert faculty will host a case-based panel discussion that focuses on screening and early diagnosis of SMA and the importance of utilizing the latest clinical data on the efficacy and safety of approved and emerging therapies.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Review the pathophysiology and therapeutic targets of SMA.
  • Apply the current recommendations for screening and early diagnosis of SMA.
  • Evaluate the latest clinical data on the efficacy and safety of approved and emerging therapies for SMA.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Review the pathophysiology and therapeutic targets of SMA.
  • Describe the current recommendations for screening and early diagnosis of SMA.
  • Evaluate the latest clinical data on the efficacy and safety of approved and emerging therapies for SMA.

Financial Support

Supported by educational grants from Biogen MA, Inc. and Genentech.

Target Audience

Pediatricians, neurologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-20-001-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

ABPN MOC Credit:
Note to ABPN Diplomates:
ABPN Diplomates may select any activity relevant to their practice to count towards ABPN MOC requirements.

ABP MOC Credit:
Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Ciafaloni reports that she is on the advisory committee for AveXis, Inc. and Biogen. She is on the speakers bureau for Biogen.

Dr. Brandsema reports that he received a grant from Biogen (CHOP Neuromuscular fellowship). He receives research support from AveXis, Inc. and Biogen (Site PI for clinical trials, is on the advisory committee for AveXis, Inc. and Biogen and is a consultant for AveXis, Inc.; Biogen and Roche/Genentech, Inc.

Dr. Kuntz reports that she received research support from Audentes Therapeutics; AveXis, Inc.; Biogen and Sarepta Therapeutics provided support for clinical research. Funds direct to institution. She is on the advisory committee for Audentes Therapeutics; Biogen; Cytokinetics, Inc.; F. Hoffmann-La Roche Ltd and Sarepta Therapeutics.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kavitha Ramachandran, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TV-109-010720-90